You are here

An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM108164-01A1
Agency Tracking Number: R43GM108164
Amount: $218,331.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ASHLAND, MA 01721-1717
United States
DUNS: 147365936
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (508) 881-6771
Business Contact
Phone: (508) 739-8213
Research Institution

DESCRIPTION (provided by applicant): The perioral route for drug administration remains the most convenient way of clinical therapy and is preferred by patients, however, good bioavailability is a necessary characteristic of new candidate therapeutics. A key parameter for determining oral bioavailability is drug transport and permeability across the small intestine (SI) epithelium. Therefore, in vitro models of SI epithelium that accurately predict in vivo human transport/permeability of candidate drugs are of high interest to the pharmaceutical industry. Currently available in vitro models have significant deficiencies which limit their utility for dru development applications, including poor correlation to in vivo human carrier-mediated transport and parcellular permeation, as well as a lack of in vivo human small intestine metabolic enzyme activity. The current proposal aims to develop an in vitro human SI for use in pharmaceutical development applications. The SI model will consist of primary huma

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government